Skip to content

Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02257957
Enrollment
30
Registered
2014-10-07
Start date
2014-11-30
Completion date
2016-04-20
Last updated
2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye, Sjogren Syndrome

Brief summary

Dry eye is a chronic condition that decreases function and affect visual function with severe discapacity until now treatments are based in artificial eye drops. Platelet rich plasma has emerged as a strategy for cellular restoration, the purpose of this study is to evaluate their effects in lacrimal production and safety of this intervention in patients with severe dry eye.

Detailed description

Dry eye is a chronic condition that decreases function and affect visual function with severe discapacity until now treatments are based in artificial eye drops. Platelet rich plasma has emerged as a strategy for cellular restoration, the purpose of this study is to evaluate their effects in lacrimal production and safety of this intervention in patients with severe dry eye.

Interventions

DRUGPRP injection
DRUGStandard care Hyaluronic acid eye drops

: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90

Sponsors

Universidad Nacional de Colombia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* • Patients with symptomatic Dry eye * Shirmer ≤10 mm in 5 min * BUT ≤10 seconds * Corneal staining ≥3 * Age range: 18 years and older. * Both genders and all ethnic groups comparable with the local community. * Able to understand and willing to sign a written informed consent * Able and willing to cooperate with the investigational plan. * Able and willing to complete all mandatory follow-up visits.

Exclusion criteria

* • Patients who are currently engaged in another clinical trial, unwilling or unable to give consent, to accept randomization, or to return for scheduled visits. * Children under 18. * Pregnant women or expecting to be pregnant during the study. * Systemic immune deficient conditions such as AIDS or under systemic immunosuppressant. * Concomitant use of systemic antibiotics or steroids. * Contact lens wear * Active ocular infection or allergy * Unable to close eyes or uncontrolled blinking

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Ocular Surface Staining90 daysSurface damage to the exposed eye, assessed by staining, is graded against standard charts. According to the Oxford grade panel (Oxford Scale), the staining was graded and was classified from grade 0 to grade V (0 to 5 score). The minimum value of this scale was 0, which indicating absent surface damage, and the maximum value was 5, which meaning severe surface damages.
Change From Baseline in Shirmer Test90 daysThe Schirmer test I (performed without anaesthesia) was completed before any drops were instilled in the eye. Standardised Schirmer strips (Biotech Vision Care, Gandhinagar, India) were bent at the notch and placed carefully over the lower lid margin as far as possible towards the temporal angle of the lids. The patient was instructed to keep his/her eyelids closed during the test. The strips remained in place for 5 min. After 5 min, the amount of moisture in each strip was measured using a millimetre scale

Secondary

MeasureTime frameDescription
Change From Baseline in Ocular Surface Disease Index (OSDI)90 daysThe OSDI consists of 12 questions on items related to the assessment of symptoms, functional limitations and environmental factors related to dry eye. It is graded on a scale of 0-4, with 0 indicating none of the time, 1 for some of the time, 2 for half of the time, 3 for most of the time and 4 indicating all the time. This is a valid and reliable instrument for measuring the severity of dry eye. The total OSDI score was then calculated by the following formula: OSDI = (sum of scores for all questions answered) × 100/(total number of questions answered) × 4). A score of 0-100 was obtained, related to the extent of dry eye, which a higher score representing greater symptoms severity.

Participant flow

Participants by arm

ArmCount
Platelet -Rich Plasma (PRP)
15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90 PRP injection
15
Standard Care
15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90 Standard care Hyaluronic acid eye drops: : 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
15
Total30

Baseline characteristics

CharacteristicPlatelet -Rich Plasma (PRP)Standard CareTotal
Age, Continuous52.9 years
STANDARD_DEVIATION 3.5
52.7 years
STANDARD_DEVIATION 3.5
52.7 years
STANDARD_DEVIATION 3.5
Sex: Female, Male
Female
14 Participants14 Participants28 Participants
Sex: Female, Male
Male
1 Participants1 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 150 / 15
serious
Total, serious adverse events
0 / 150 / 15

Outcome results

Primary

Change From Baseline in Ocular Surface Staining

Surface damage to the exposed eye, assessed by staining, is graded against standard charts. According to the Oxford grade panel (Oxford Scale), the staining was graded and was classified from grade 0 to grade V (0 to 5 score). The minimum value of this scale was 0, which indicating absent surface damage, and the maximum value was 5, which meaning severe surface damages.

Time frame: 90 days

ArmMeasureValue (MEAN)Dispersion
Platelet -Rich Plasma (PRP)Change From Baseline in Ocular Surface Staining1.2 score on a scaleStandard Deviation 0.18
Standard CareChange From Baseline in Ocular Surface Staining2.4 score on a scaleStandard Deviation 0.18
Primary

Change From Baseline in Shirmer Test

The Schirmer test I (performed without anaesthesia) was completed before any drops were instilled in the eye. Standardised Schirmer strips (Biotech Vision Care, Gandhinagar, India) were bent at the notch and placed carefully over the lower lid margin as far as possible towards the temporal angle of the lids. The patient was instructed to keep his/her eyelids closed during the test. The strips remained in place for 5 min. After 5 min, the amount of moisture in each strip was measured using a millimetre scale

Time frame: 90 days

ArmMeasureValue (MEAN)Dispersion
Platelet -Rich Plasma (PRP)Change From Baseline in Shirmer Test9.2 mmStandard Deviation 1
Standard CareChange From Baseline in Shirmer Test5.3 mmStandard Deviation 0.7
Secondary

Change From Baseline in Ocular Surface Disease Index (OSDI)

The OSDI consists of 12 questions on items related to the assessment of symptoms, functional limitations and environmental factors related to dry eye. It is graded on a scale of 0-4, with 0 indicating none of the time, 1 for some of the time, 2 for half of the time, 3 for most of the time and 4 indicating all the time. This is a valid and reliable instrument for measuring the severity of dry eye. The total OSDI score was then calculated by the following formula: OSDI = (sum of scores for all questions answered) × 100/(total number of questions answered) × 4). A score of 0-100 was obtained, related to the extent of dry eye, which a higher score representing greater symptoms severity.

Time frame: 90 days

ArmMeasureValue (MEAN)Dispersion
Platelet -Rich Plasma (PRP)Change From Baseline in Ocular Surface Disease Index (OSDI)34 score on a scaleStandard Deviation 4
Standard CareChange From Baseline in Ocular Surface Disease Index (OSDI)55 score on a scaleStandard Deviation 2.5

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026